Shares of OraSure Technologies Inc (NASDAQ:OSUR) climbed 4.1% in premarket trading Wednesday after the company said the U.S. Food and Drug Administration granted clearance for its at-home urine collection kit intended for sexually transmitted infection (STI) molecular testing.
The approval authorizes use of OraSure’s Colli-Pee Dx Urine Collection Kit together with Roche’s cobas molecular testing equipment to detect four pathogens: Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium. The cleared workflow supports collection of first-void urine samples at home, and is intended for use by both male and female patients.
OraSure’s kit incorporates NucleoPrecision Technology, described by the company as a proprietary chemistry that stabilizes DNA and RNA. That stabilization capability allows self-collected urine to be maintained at ambient temperatures while in transit, so laboratories can accept specimens mailed directly from patients’ homes without additional cold-chain measures.
The Colli-Pee Dx collection device is engineered to capture volumetric, first-void urine and to preserve an optimal ratio between sample and preservative for molecular STI assays. Laboratories that receive these specimens can run them on Roche’s cobas 5800, 6800 and 8800 molecular diagnostic systems. The clearance also makes it possible for healthcare providers to prescribe the kit for patients and for laboratories to process mailed-in samples via Roche’s automated laboratory platforms.
OraSure said the authorization enables a mail-in workflow that supports high-volume molecular STI testing across laboratories and health systems. The company noted that its subsidiary, DNA Genotek, will handle sale of the Colli-Pee Dx Urine Collection Kit.
In a company statement, Carrie Eglinton Manner, Chief Executive Officer of OraSure, stated that the clearance connects people to care that is more accessible, convenient, private and personalized, underscoring the intended patient-facing benefits of the cleared device.
OraSure is headquartered in Bethlehem, Pennsylvania, and develops both point-of-need and home diagnostic tests along with sample management solutions. The FDA clearance described by the company focuses on the collection device and its compatibility with established molecular testing platforms rather than on a separate diagnostic assay.
Summary - The FDA cleared OraSure’s Colli-Pee Dx Urine Collection Kit for at-home first-void urine collection paired with Roche cobas molecular systems to detect four STI pathogens. The kit uses NucleoPrecision Technology to stabilize nucleic acids at ambient temperatures and will be sold by OraSure’s DNA Genotek subsidiary, enabling a mail-in workflow for laboratories and health systems.
Key Points
- OraSure’s stock rose 4.1% in premarket trading Wednesday following the FDA clearance of its at-home urine collection kit for STI testing.
- The cleared workflow pairs the Colli-Pee Dx kit with Roche cobas 5800, 6800 and 8800 molecular diagnostic systems to detect C. trachomatis, N. gonorrhoeae, T. vaginalis and M. genitalium.
- The clearance enables a mail-in, high-volume molecular STI testing workflow for laboratories and health systems; the kit will be distributed by DNA Genotek.
Risks and Uncertainties
- The article does not provide information on expected adoption rates of the kit by healthcare providers or patients, leaving uptake uncertain.
- The piece does not address reimbursement or payer coverage for mail-in STI testing, so financial viability and billing pathways are not specified.
- The article does not detail timelines or logistics for rollout to laboratories and health systems, so the speed and scale of deployment remain unclear.